Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hybrid optimization for efficient 6G IoT traffic management and multi-routing strategy.
Sci Rep
December 2024
Computer Engineering Department, Umm Al-Qura University, Mecca, 24381, Saudi Arabia.
Efficient traffic management solutions in 6G communication systems face challenges as the scale of the Internet of Things (IoT) grows. This paper aims to yield an all-inclusive framework ensuring reliable air pollution monitoring throughout smart cities, capitalizing on leading-edge techniques to encourage large coverage, high-accuracy data, and scalability. Dynamic sensors deployed to mobile ad-hoc pieces of fire networking sensors adapt to ambient changes.
View Article and Find Full Text PDFAntiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
Neurology
November 2023
From the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Article Synopsis
- - Recent studies show that lecanemab can slow cognitive and functional decline in early Alzheimer's disease (AD), making it a promising treatment option alongside other monoclonal antibodies targeting β-amyloid.
- - The introduction of these treatments involves significant risks and challenges that differ from current AD management, requiring changes in clinical practices and infrastructure for effective use.
- - This article offers guidance for neurologists on implementing antiamyloid therapies, emphasizing patient selection, treatment monitoring, multidisciplinary collaboration, and the importance of evolving practices to improve patient outcomes.
Questionnaire for diagnosing asthma-COPD overlap in COPD: Development of ACO screening questionnaire (ACO-Q).
Allergol Int
July 2023
Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Background: The considerable prevalence and worse outcomes of asthma-COPD overlap (ACO) in COPD have been reported, and optimal introduction of ICS is essential for ACO. However, diagnostic criteria for ACO consist of multiple laboratory tests, which is challenging during this COVID-19 era. The purpose of this study was to create a simple questionnaire to diagnose ACO in patients with COPD.
View Article and Find Full Text PDFArticle Synopsis
- - Broomcorn millet, a resilient cereal, showed increased yield and improved nutrient concentrations (like Mg, Mn, and B) when grown under elevated CO levels compared to ambient CO, despite a decrease in protein content.
- - The study ran for three years using open-top chambers (OTC) to assess how elevated CO impacted yield and nutrient quality, revealing that other nutrients like starch and oil remained stable while some amino acids decreased, affecting protein levels.
- - Overall, broomcorn millet's enhanced nutritional profile under climate change conditions suggests it could be a valuable crop for addressing hidden hunger and could aid in developing more nutritious plants.
Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era.
Healthcare (Basel)
July 2022
Cardiology and Internal Medicine Department, Theodor Burghele Clinical Hospital, 050653 Bucharest, Romania.
Patients with nonvalvular atrial fibrillation (NVAF) have five times higher risk of stroke than the general population. Anticoagulation (ACO) in NVAF is a class I indication after assessing the CHA2DS2-VASc and HAS-BLED scores. However, in the real world, NVAF patients receive less ACO than needed due to patients' comorbidities that can be assessed by the Charlson comorbidity index (CCI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!